Literature DB >> 16085909

Noninfectious virus-like particle antigen for detection of swine vesicular disease virus antibodies in pigs by enzyme-linked immunosorbent assay.

Young-Joon Ko1, Kang-Seuk Choi, Jin-Ju Nah, David J Paton, Jae-Ku Oem, Ginette Wilsden, Shien-Young Kang, Nam-In Jo, Joo-Ho Lee, Jae-Hong Kim, Hee-Woo Lee, Jong-Myeong Park.   

Abstract

An inactivated SVDV antigen is used in current enzyme-linked immunosorbent assays (ELISAs) for the detection of antibodies to swine vesicular disease virus (SVDV). To develop a noninfectious recombinant alternative, we produced SVDV-like particles (VLPs) morphologically and antigenically resembling authentic SVDV particles by using a dual baculovirus recombinant, which expresses simultaneously the P1 and 3CD protein genes of SVDV under different promoters. Antigenic differences between recombinant VLPs and SVDV particles were not statistically significant in results obtained with a 5B7-ELISA kit, indicating that the VLPs could be used in the place of SVDV antigen in ELISA kits. We developed a blocking ELISA using the VLPs and SVDV-specific neutralizing monoclonal antibody 3H10 (VLP-ELISA) for detection of SVDV serum antibodies in pigs. The VLP-ELISA showed a high specificity of 99.9% when tested with pig sera that are negative for SVDV neutralization (n=1,041). When tested using sera (n=186) collected periodically from pigs (n=19) with experimental infection with each of three different strains of SVDV, the VLP-ELISA detected SVDV serum antibodies as early as 3 days postinfection and continued to detect the antibodies from all infected pigs until termination of the experiments (up to 121 days postinfection). This test performance was similar to that of the gold standard virus neutralization test and indicates that the VLP-ELISA is a highly specific and sensitive method for the detection of SVDV serum antibodies in pigs. This is the first report of the production and diagnostic application of recombinant VLPs of SVDV. Further potential uses of the VLPs are discussed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16085909      PMCID: PMC1182192          DOI: 10.1128/CDLI.12.8.922-929.2005

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  39 in total

Review 1.  Production of core and virus-like particles with baculovirus infected insect cells.

Authors:  Luis Maranga; Pedro E Cruz; John G Aunins; Manuel J T Carrondo
Journal:  Adv Biochem Eng Biotechnol       Date:  2002       Impact factor: 2.635

2.  Characterization of neutralization sites on the circulating variant of swine vesicular disease virus (SVDV): a new site is shared by SVDV and the related coxsackie B5 virus.

Authors:  Belén Borrego; Elena Carra; Juan Antonio García-Ranea; Emiliana Brocchi
Journal:  J Gen Virol       Date:  2002-01       Impact factor: 3.891

3.  A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers.

Authors:  T G Evans; W Bonnez; R C Rose; S Koenig; L Demeter; J A Suzich; D O'Brien; M Campbell; W I White; J Balsley; R C Reichman
Journal:  J Infect Dis       Date:  2001-04-24       Impact factor: 5.226

4.  Immune recognition of swine vesicular disease virus structural proteins: novel antigenic regions that are not exposed in the capsid.

Authors:  M A Jiménez-Clavero; A Douglas; T Lavery; J A Garcia-Ranea; V Ley
Journal:  Virology       Date:  2000-04-25       Impact factor: 3.616

5.  Isotype specific ELISAs to detect antibodies against swine vesicular disease virus and their use in epidemiology.

Authors:  A Dekker; F van Hemert-Kluitenberg; C Baars; C Terpstra
Journal:  Epidemiol Infect       Date:  2002-04       Impact factor: 2.451

6.  Validation of a screening liquid phase blocking ELISA for swine vesicular disease.

Authors:  A Dekker; P L Moonen; C Terpstra
Journal:  J Virol Methods       Date:  1995-02       Impact factor: 2.014

7.  Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine.

Authors:  C D Harro; Y Y Pang; R B Roden; A Hildesheim; Z Wang; M J Reynolds; T C Mast; R Robinson; B R Murphy; R A Karron; J Dillner; J T Schiller; D R Lowy
Journal:  J Natl Cancer Inst       Date:  2001-02-21       Impact factor: 13.506

Review 8.  Swine vesicular disease: an overview.

Authors:  F Lin; R P Kitching
Journal:  Vet J       Date:  2000-11       Impact factor: 2.688

9.  Expression and self-assembly in baculovirus of porcine enteric calicivirus capsids into virus-like particles and their use in an enzyme-linked immunosorbent assay for antibody detection in swine.

Authors:  M Guo; Y Qian; K O Chang; L J Saif
Journal:  J Clin Microbiol       Date:  2001-04       Impact factor: 5.948

10.  Development of two novel monoclonal antibody-based ELISAs for the detection of antibodies and the identification of swine isotypes against swine vesicular disease virus.

Authors:  E Brocchi; A Berlinzani; D Gamba; F De Simone
Journal:  J Virol Methods       Date:  1995-03       Impact factor: 2.014

View more
  9 in total

1.  Expression and purification of virus like particles (VLPs) of foot-and-mouth disease virus in Eri silkworm (Samia cynthia ricini) larvae.

Authors:  Manoj Kumar; P Saravanan; S K Jalali
Journal:  Virusdisease       Date:  2015-11-24

2.  Validation of a competitive enzyme-linked immunosorbent assay to improve the serological diagnosis of swine vesicular disease.

Authors:  Ming Yang; Leanne McIntyre; Wanhong Xu; Emiliana Brocchi; Santina Grazioli; Kathleen Hooper-McGrevy; Charles Nfon
Journal:  Can J Vet Res       Date:  2022-04       Impact factor: 0.897

3.  Immunogenicity and safety of virus-like particle of the porcine encephalomyocarditis virus in pig.

Authors:  Hye-Young Jeoung; Won-Ha Lee; WooSeog Jeong; Bo-Hye Shin; Hwan-Won Choi; Hee Soo Lee; Dong-Jun An
Journal:  Virol J       Date:  2011-04-15       Impact factor: 4.099

4.  Assembly of recombinant Israeli Acute Paralysis Virus capsids.

Authors:  Junyuan Ren; Abigail Cone; Rebecca Willmot; Ian M Jones
Journal:  PLoS One       Date:  2014-08-25       Impact factor: 3.240

5.  Generation, characterization, and application in serodiagnosis of recombinant swine vesicular disease virus-like particles.

Authors:  Wanhong Xu; Melissa Goolia; Tim Salo; Zhidong Zhang; Ming Yang
Journal:  J Vet Sci       Date:  2017-08-31       Impact factor: 1.672

Review 6.  Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development.

Authors:  Natasha Kushnir; Stephen J Streatfield; Vidadi Yusibov
Journal:  Vaccine       Date:  2012-11-06       Impact factor: 3.641

7.  A review of vaccine development and research for industry animals in Korea.

Authors:  Nak-Hyung Lee; Jung-Ah Lee; Seung-Yong Park; Chang-Seon Song; In-Soo Choi; Joong-Bok Lee
Journal:  Clin Exp Vaccine Res       Date:  2012-07-31

8.  Efficient production of foot-and-mouth disease virus empty capsids in insect cells following down regulation of 3C protease activity.

Authors:  Claudine Porta; Xiaodong Xu; Silvia Loureiro; Saravanan Paramasivam; Junyuan Ren; Tara Al-Khalil; Alison Burman; Terry Jackson; Graham J Belsham; Stephen Curry; George P Lomonossoff; Satya Parida; David Paton; Yanmin Li; Ginette Wilsden; Nigel Ferris; Ray Owens; Abhay Kotecha; Elizabeth Fry; David I Stuart; Bryan Charleston; Ian M Jones
Journal:  J Virol Methods       Date:  2012-11-19       Impact factor: 2.014

9.  Efficient self-assembly and protective efficacy of infectious bursal disease virus-like particles by a recombinant baculovirus co-expressing precursor polyprotein and VP4.

Authors:  Hyun-Jeong Lee; Ji-Ye Kim; Soo-Jeong Kye; Hee-Jung Seul; Suk-Chan Jung; Kang-Seuk Choi
Journal:  Virol J       Date:  2015-10-26       Impact factor: 4.099

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.